← Eichor
Study identifier: NCT06222723 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

LAssa Fever Adjunct Treatment With DEXamethasone

Condition: Lassa Fever  ·  Sponsor: Bernhard Nocht Institute for Tropical Medicine

PhasePhase 2
Planned participants42
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

Dexamethasone is a corticosteroid which can modulate inflammatory-mediated tissue damage associated with a wide range of infectious diseases. Dexamethasone is routinely used for treatment of tuberculous meningitis and for pneumococcal meningitis in adults. In Coronavirus Disease 2019 (COVID-19) dexamethasone is also effectively preventing immune mediated damage of the lungs. There is also indication that dexamethasone may be promising in severe LF.

This description comes directly from the study's public registry record.

Talk to the study team

Mirjam Groger, Dr.  ·  +4940285380480  ·  groger@bnitm.de

Stephan Günther, Prof.  ·  +4940285380547  ·  guenther@bnitm.de

Always discuss trial participation with your own doctor first.

Locations (1)

Irrua Specialist Teaching HospitalIrrua, Edo, NigeriaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06222723